Tipsheet
What matters at India’s listed companies
Medical Equipment · Micro cap

Saurabh Goyal to own 68% of Nureca after promoter family settlement

Aryan and Payal Goyal transfer their entire 33.7% stake to chairman Saurabh Goyal, who will also take over as CEO after a planned resignation.

5 earlier stories on Nureca Ltd.
Mkt cap₹226 cr
P/E108.64×
ROE0.44%
Debt / eq.0.01
68.09% Saurabh Goyal's new voting power after family settlement

What's new

  • Aryan and Payal Goyal transfer 33.7% stake to Saurabh Goyal, raising his holding to 68.09%.
  • Aryan Goyal to resign as CEO and director, conditional on settlement completion.
  • Nureca says it is not a party to the agreement and has not verified its contents.

Why this matters

The settlement consolidates control in Saurabh Goyal, concentrating voting power in one person at a nano-cap already struggling with losses. The transfer, worth over ₹76 crore at current market cap, removes counterweights on the board and hands the chairman near-total authority without independent verification of the agreement.

What we're watching

  • Whether Saurabh Goyal formally assumes the CEO role and what strategic shifts follow.
  • How minority shareholders react to the ownership concentration and board changes.
  • Any regulatory scrutiny given the company's disclaimer on the settlement's contents.

The full read

Nureca's promoter structure just got a lot simpler—and a lot more concentrated. Under a family settlement dated June 17, 2026, Aryan Goyal and Payal Goyal will transfer their entire 33.7% stake to chairman Saurabh Goyal, lifting his voting rights from 34.35% to 68.09%. In the same move, Aryan Goyal will resign as CEO and director, pending completion. The company says it is not a party and has not verified the terms. At ₹227 crore market cap, the transferred shares are worth over ₹76 crore — a huge reorganisation for a nano-cap that posted ₹35 crore in sales last quarter and a ₹6 crore net loss. The settlement gives Saurabh Goyal near-absolute control. For a loss-making medical-equipment firm with a P/E of 108, that concentration could mean faster decision-making or less accountability. The open question is whether the new majority owner steers the company toward a turnaround or deeper trouble.

Questions answered

Why are Aryan and Payal Goyal transferring their shares?
The transfer is part of a family settlement for succession planning and reallocation of ownership interests among promoter family members, as per the company.
What is the value of the shares being transferred?
At a market cap of roughly ₹227 crore, the 33.7% stake is worth over ₹76 crore, representing a significant chunk of the company's equity.
Will Aryan Goyal remain with the company after the settlement?
No. He will step down as CEO and resign as a director, conditional on the settlement's completion.
Has Nureca verified the terms of the family settlement?
No. The company stated it is not a party to the agreement and has not independently verified its contents.
How does this affect minority shareholders?
Saurabh Goyal's voting power jumps from 34.35% to 68.09%, giving him control over shareholder resolutions without needing other votes—concentrating risk and reducing checks.
Mentioned: Saurabh Goyal · Aryan Goyal · over ₹76 cr
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Nureca Ltd.

Pharmaceuticals
₹219 cr
P/E 105.36×

Latest quarter · Mar 2026

Sales₹35 cr
Net profit−₹6 cr
Op. margin−16.3%
EPS−₹6.38

Strength & growth

Debt / equity0.01×
Current ratio15.32×
Financials via Tijori — a research aid, not investment advice.NURECA on Tijori
  1. 20 Jun 2026 · 11:41 AM IST Saurabh Goyal to own 68% of Nureca after promoter family settlement
  2. today Nureca hits 2.4M users on health platform, adds AI analytics
  3. 11d ago Nureca promoter buys 60,842 shares, nudging stake to 34.35%
  4. 19d ago Nureca raised its Punjab plant budget 28%. It calls the first number a typo.
  5. 22d ago Nureca posts FY25 results and adds a whole-time director